• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

Opinion
Video

Experts on Alzheimer disease discuss how the introduction of disease-modifying therapies has impacted the treatment landscape.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following question(s):

      • What has been the clinical impact and the target patients for the use of anti-amyloid β monoclonal antibodies?
        • Aducanumab approved by the FDA in 2021; development and commercialization discontinued on Jan 31, 2024
        • Lecanemab approved by the FDA in 2023
      Related Content
      © 2025 MJH Life Sciences
      AJMC®
      All rights reserved.